Medical device company Soliton Inc. SOLY shares are trading higher again after the company highlighted its preclinical results for its new RAP device, which "is a potentially important new way to treat cellulite and improve the appearance of the skin."
Why It's Important
Soliton claims its RAP technology has the ability to reduce cellulite and aid in tattoo removal, according to Soliton.
"While the proof-of-concept clinical trial results we have recently announced regarding the improvement in the appearance of cellulite have been very encouraging," said CEO Dr. Chris Capelli. "Understanding the basic science and biology behind these results is very important. We believe the discovery we are outlining here helps explain the promising results we saw from this trial, as well as setting the foundation for a platform technology that may have potential in a number of aesthetic indications."
Price Action
Soliton's stock traded higher by 15.6 percent to $17.51 per share at time of publication.
The Benzinga's quotes page shows Soliton has about 5 million shares in its float, which could make it a low-float play.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
